Reading this on a mobile device? Try our optimized mobile version here:

October 25, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • FDA compassionate-use program faces obstacles
    The FDA's compassionate-use program allows patients with serious or life-threatening conditions to get experimental drugs after all other options have failed. Nearly 1,200 patients took advantage of the program last year, and the FDA is hoping to reach even more patients through online seminars for health care providers. But some drugmakers hesitate to make unapproved drugs available to qualified patients. Health insurers typically do not cover experimental treatments, although many makers supply free drugs for the program. The Wall Street Journal (10/22) LinkedInFacebookTwitterEmail this Story
Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenges faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio.
  Health Care & Policy 
  • FDA expedites review of Ariad's leukemia drug ponatinib
    Ariad Pharmaceuticals' experimental drug ponatinib obtained priority-review status from the FDA as a treatment for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The agency is expected to decide on approval by March 27. Reuters (10/24) LinkedInFacebookTwitterEmail this Story
  • Allegro's genomic test shows promise in lung cancer trial
    Early results of a clinical study found that Allegro Diagnostics' BronchoGen genomic assay proved accurate in diagnosing lung cancer 94% of the time when used with bronchoscopy, compared with 74% when bronchoscopy was used by itself. Full results from the 730-patient trial will be released later this year, which will be used to back the firm's regulatory application for the test. Mass High Tech (Boston) (10/23) LinkedInFacebookTwitterEmail this Story
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Company & Financial News 
  • Funding round brings in $34.5M for microRNA-based cancer drugmaker
    Mirna Therapeutics, which develops microRNA-based cancer treatments, obtained $34.5 million in a Series C financing round. The money will permit Mirna to bring its lead candidate, MRX34, through proof-of-concept trials. The firm plans to submit an investigational new drug application early next year then launch early-stage studies in patients with advanced or metastatic liver cancer. (10/24) LinkedInFacebookTwitterEmail this Story
  • Cellular Dynamics lands up to $7M stem cell contract from NIH
    The NIH awarded Cellular Dynamics International a three-year contract worth as much as $7 million to provide human induced pluripotent stem cell lines and permanently differentiated cells for use in preclinical testing. "This contract enables NIH researchers to easily access our human iPS cell-derived cells and accelerate the pace of their research," CDI Chief Operating Officer Chris Parker said. GenomeWeb Daily News (free registration) (10/24) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  Food & Agriculture 
  • Canada OKs Dow's herbicide-tolerant corn and soybeans
    Dow AgroSciences' 2,4-D-herbicide-resistant Enlist corn and soybeans have passed three of four evaluations by Health Canada and the Canadian Food Inspection Agency in the process for achieving approval for human and animal consumption. Dow plans a Canadian launch of the corn seeds in time for spring and the soybeans by 2015. Ottawa Citizen (Ontario) (10/22) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Novozymes exec concerned about EU plan capping crop-based fuels
    The EU's plan to cap the use of crop-based biofuels would drive away investors from advanced biofuels and unnecessarily punish first-generation biofuels, according to Lars Hansen, president of Novozymes Europe. "Our company and other companies are investing everywhere and we would like to invest in Europe as well, but I would be surprised if anybody would invest based on this [announcement]," Hansen said. BusinessGreen (U.K.) (10/24) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

In any field, find the strangest thing and then explore it."
--John Archibald Wheeler,
American theoretical physicist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information